Long-term physiologic and oncologic outcomes of XXXX in @entity5 .

@entity1 @entity5 @entity1636 @entity432 @entity3969 @entity715 @entity4177
BACKGROUND: The long-term physiologic and oncologic outcomes of treatment for inferior vena cava (IVC) @entity715 in @entity1 with malignant @entity5 are unclear. METHODS: We conducted a retrospective review of @entity1 with @entity715 treated at our institution between January 1996 and December 2011. Extent of @entity5 @entity715 was classified using the Hinman system. Disease stage, management, and oncologic and physiologic outcomes and complications were evaluated. RESULTS: We identified 15 @entity1 (median age, 4.7years): 12 with @entity3969 , 2 with @entity4177 , and 1 with @entity1636 . Neoadjuvant chemotherapy changed Hinman levels in 2 (13%) @entity1 . IVC @entity715 resection was complete in 6 (40%) @entity1 , partial in 7 (47%) @entity1 , and not performed in 1 (6.7%) @entity1 . On follow-up imaging, 8 (53%) @entity1 ' IVCs were patent, 6 (40%) had residual @entity715 , and 1 (6.7%) was surgically interrupted. Three (20%) @entity1 had perioperative complications, and 2 (13%) experienced transient effects related to @entity432 . CONCLUSIONS: Surgical management of @entity5 @entity715 in the vena cava of @entity1 with solid @entity5 is challenging. Evidence on which to base strong treatment recommendations is lacking. Few long-term physiologic complications were observed.
